EMG
NKTR icon

ETF Managers Group’s Nektar Therapeutics NKTR Stock Holding History

ETF Managers Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,200
Closed -$351K – 756
2021
Q1 		$351K Buy
1,200
+161
+15% +$50.1K 0.01% 574
2020
Q4 		$279K Buy
1,039
+93
+10% +$24K 0.01% 556
2020
Q3 		$240K Sell
946
-550
-37% -$173K 0.01% 557
2020
Q2 		$503K Buy
+1,496
New +$467K 0.02% 269
2019
Q3 		– Sell
-1,127
Closed -$586K – 570
2019
Q2 		$586K Sell
1,127
-307
-21% -$154K 0.02% 237
2019
Q1 		$723K Sell
1,434
-126
-8% -$74.7K 0.04% 205
2018
Q4 		$769K Sell
1,560
-222
-12% -$134K 0.04% 203
2018
Q3 		$1.63M Buy
1,782
+456
+34% +$389K 0.06% 141
2018
Q2 		$6.6M Buy
+1,326
New +$1.53M 0.48% 45

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

ETF Managers Group's NKTR Position: Q2 2021 in Review

ETF Managers Group sold out of Nektar Therapeutics (NKTR) in Q2 2021, closing a stake of 1,200 shares — an estimated $351K sold.

ETF Managers Group first reported a position in NKTR in Q2 2018 and held it in 9 quarters. The position peaked at $6.6M in Q2 2018. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2021.

  • ETF Managers Group reported no remaining Nektar Therapeutics position as of Q2 2021 after selling out during the quarter.
  • ETF Managers Group sold 1,200 Nektar Therapeutics shares in Q2 2021, an estimated $351K.
  • ETF Managers Group first reported a position in Nektar Therapeutics in Q2 2018 and held it in 9 quarters.
  • ETF Managers Group's Nektar Therapeutics position peaked at $6.6M in Q2 2018.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2021.

Based on ETF Managers Group's 13F filing for Q2 2021, filed 16 Aug 2021.